These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18508797)

  • 21. Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador.
    Paz-Y-Miño C; Arévalo M; Sánchez ME; Cañizares C; Leone PE
    Arch Med Res; 2007 Apr; 38(3):364-5. PubMed ID: 17350491
    [No Abstract]   [Full Text] [Related]  

  • 22. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature.
    Frustaci A; Breccia M; Cannella L; Stefanizzi C; Alimena G
    Leuk Res; 2009 Jan; 33(1):200-1. PubMed ID: 18452989
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
    Aftimos P; Nasr F
    Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

  • 27. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
    Bhagavathi S; Borromeo V; Desai H; Crisan D
    Ann Clin Lab Sci; 2008; 38(4):405-9. PubMed ID: 18988937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effects of imatinib mesylate on immune globulin and T cell subset in patients with chronic myelocytic leukemia].
    Gui RR; Zhang YL; Fang BJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):225-6. PubMed ID: 22781613
    [No Abstract]   [Full Text] [Related]  

  • 31. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 32. Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?
    Faber E
    Leuk Res; 2009 May; 33(5):605-6. PubMed ID: 19062091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?
    Kanda Y; Okamoto S; Tauchi T; Kizaki M; Inokuchi K; Yabe M; Yokoyama K; Ito Y; Kimura Y; Higashihara M; Bessho M; Ando K; Chiba S; Kurokawa M; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
    Am J Hematol; 2008 Nov; 83(11):835-9. PubMed ID: 18785644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A PDE model for imatinib-treated chronic myelogenous leukemia.
    Kim PS; Lee PP; Levy D
    Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
    Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ
    Leuk Res; 2009 Nov; 33(11):1459-62. PubMed ID: 19446878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
    Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
    Br J Haematol; 2008 Sep; 142(6):992-5. PubMed ID: 18573108
    [No Abstract]   [Full Text] [Related]  

  • 39. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.